EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$50.61

Market cap

$12.54B

P/E Ratio

15.38

Dividend/share

N/A

EPS

$3.29

Enterprise value

$12.42B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 55
Relative Valuation: Rel. Valuation: 75
Relative Profitability: Rel. Profitability: 99

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our ...

Highlights
The company's EPS has surged by 53% YoY and by 5% QoQ
The company's net income rose by 43% YoY and by 3.3% QoQ
The company's equity fell by 9% YoY and by 4.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN CRIS

Key stats

What are the main financial stats of EXEL

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
0.46%
1 week
-3.05%
1 month
-9.69%
1 year
31.49%
YTD
15.47%
QTD
-6.98%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$2.44B
Gross profit
$2.35B
Operating income
$971.51M
Net income
$860.62M
Gross margin
96.5%
Net margin
35.3%
The company's net income rose by 43% YoY and by 3.3% QoQ
Exelixis's operating income has increased by 39% YoY and by 3.7% QoQ
The net margin has increased by 31% YoY
EXEL's operating margin is up by 27% year-on-year

Price vs fundamentals

How does EXEL's price correlate with its fundamentals

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
15.38
P/B
6.9
P/S
5.21
EV/EBIT
12
EV/EBITDA
11.42
EV/Sales
5.1
The company's EPS has surged by 53% YoY and by 5% QoQ
The P/E is 43% below the 5-year quarterly average of 27.1
EXEL's P/B is 82% above its 5-year quarterly average of 3.8 and 17% above its last 4 quarters average of 5.9
The company's equity fell by 9% YoY and by 4.8% QoQ
EXEL's price to sales (P/S) is 21% higher than its 5-year quarterly average of 4.3 and 2.2% higher than its last 4 quarters average of 5.1
The revenue has grown by 9% YoY and by 2.5% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The ROIC has soared by 54% YoY and by 8% from the previous quarter
The company's return on equity has surged by 53% YoY and by 6% QoQ
The ROA has soared by 52% YoY and by 4.9% from the previous quarter
The company's return on sales rose by 22% YoY

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's quick ratio is up by 8% since the previous quarter
The company's total assets fell by 7% YoY and by 3.8% QoQ
The debt is 91% less than the equity
The company's equity fell by 9% YoY and by 4.8% QoQ
The debt has decreased by 8% YoY and by 2.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.